-
Posted by
Two Blokes Apr 25 -
Filed in
Stock
-
5 views
The first a approved fully-human, dual-acting interleukin-23 (IL-23) inhibitor in moderately to severely active ulcerative colitis, 1 , 2 , 3 , 4 , 5 guselkumab showed statistically higher rates of endoscopic normalisation b at Week 44 compared with placebo. 2, 6 , 7 , 8 , 9
